公开(公告)号：US20190321360A1

公开(公告)日：2019-10-24

申请号：US16365742

申请日：2019-03-27

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Jorden Kass ,  Byung-Chul Suh ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Xuri Gao ,  Yat Sun Or

IPC: A61K31/4985 ,  A61K45/06 ,  A61K31/7105 ,  C07D487/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10407445B2

公开(公告)日：2019-09-10

申请号：US15007567

申请日：2016-01-27

Applicant: ENANTA PHARMACEUTICALS, INC. ,  NOVARTIS AG

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Xuri Gao ,  Yat Sun Or ,  Zachary Kevin Sweeney

IPC: C07D491/107 ,  C07D519/00 ,  A61K31/4178 ,  A61K45/06 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/427 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/21 ,  C07D405/14 ,  C07D403/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190060258A1

公开(公告)日：2019-02-28

申请号：US16114842

申请日：2018-08-28

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/401 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20170217974A1

公开(公告)日：2017-08-03

申请号：US15421777

申请日：2017-02-01

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Meizhong Jin ,  Jorden Kass ,  Hui Cao ,  Xuri Gao ,  Wei Li ,  Xiaowen Peng ,  Yao-Ling Qiu

IPC: C07D487/10 ,  A61K31/46 ,  C07D403/12 ,  A61K31/4178 ,  C07D221/20 ,  C07D451/02 ,  C07D471/10 ,  A61K31/435 ,  C07D451/06 ,  A61K31/438

CPC classification number: C07D487/10 ,  A61K31/4178 ,  A61K31/435 ,  A61K31/438 ,  A61K31/46 ,  C07D221/20 ,  C07D403/12 ,  C07D451/02 ,  C07D451/06 ,  C07D471/10

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20170014408A1

公开(公告)日：2017-01-19

申请号：US15209150

申请日：2016-07-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Meizhong Jin ,  Jorden Kass ,  Xuri Gao ,  Yat Sun Or

IPC: A61K31/506 ,  C07D417/14 ,  C07D417/12 ,  C07F9/6558 ,  A61K31/683 ,  C07D487/04 ,  C07D239/20 ,  A61K31/505 ,  C07D498/08 ,  A61K31/5386 ,  A61K31/5377 ,  C07D451/06 ,  A61K45/06 ,  C07D403/04

CPC classification number: A61K31/506 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/683 ,  A61K45/06 ,  C07D239/20 ,  C07D403/04 ,  C07D417/12 ,  C07D417/14 ,  C07D451/06 ,  C07D487/04 ,  C07D498/08 ,  C07F9/65583 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20160159843A1

公开(公告)日：2016-06-09

申请号：US14959364

申请日：2015-12-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Wei Li ,  Xuri Gao ,  Xiaowen Peng ,  Jorden Kass ,  Yat Sun Or

IPC: C07H19/06

CPC classification number: C07H19/06 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076

Abstract: The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

公开(公告)号：US20230159546A1

公开(公告)日：2023-05-25

申请号：US17989103

申请日：2022-11-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jorden Kass ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xuri Gao ,  Xiaowen Peng ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230115107A1

公开(公告)日：2023-04-13

申请号：US17720654

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  C07D487/12 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11596611B2

公开(公告)日：2023-03-07

申请号：US17166046

申请日：2021-02-03

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220162231A1

公开(公告)日：2022-05-26

申请号：US17531844

申请日：2021-11-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Yong He ,  Xuechao Xing ,  Hui Cao ,  Xuri Gao ,  Xiaowen Peng ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.